Saad Usmani, Pierre Bories, Cristina Gasparetto, David Dingli, Sagar Lonial, David Siegel, Andrew Yee, Cindy Varga, Suzanne Trudel, Laura Rosiñol Dachs, Paula Rodriguez-Otero, Salomon Manier, Jesús Berdeja, Aimaz Afrough, Warren Baker, Seyed Alireza Hasheminasab, Anjan Thakurta, Vinidhra Sridharan, Erin Flynt, Miriam Barnett, Laura Versmee, María-Victoria Mateos, Cyrille Touzeau, Alfred Chung, Vivek Roy, Edward Stadtmauer. "Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma." Blood, 2025. doi:10.1182/blood-2025-250